157 related articles for article (PubMed ID: 14630650)
1. Linking the growth inhibition response from the National Cancer Institute's anticancer screen to gene expression levels and other molecular target data.
Wallqvist A; Rabow AA; Shoemaker RH; Sausville EA; Covell DG
Bioinformatics; 2003 Nov; 19(17):2212-24. PubMed ID: 14630650
[TBL] [Abstract][Full Text] [Related]
2. Linking pathway gene expressions to the growth inhibition response from the National Cancer Institute's anticancer screen and drug mechanism of action.
Huang R; Wallqvist A; Thanki N; Covell DG
Pharmacogenomics J; 2005; 5(6):381-99. PubMed ID: 16103895
[TBL] [Abstract][Full Text] [Related]
3. Assessment of in vitro and in vivo activities in the National Cancer Institute's anticancer screen with respect to chemical structure, target specificity, and mechanism of action.
Huang R; Wallqvist A; Covell DG
J Med Chem; 2006 Mar; 49(6):1964-79. PubMed ID: 16539384
[TBL] [Abstract][Full Text] [Related]
4. Mining the National Cancer Institute's tumor-screening database: identification of compounds with similar cellular activities.
Rabow AA; Shoemaker RH; Sausville EA; Covell DG
J Med Chem; 2002 Feb; 45(4):818-40. PubMed ID: 11831894
[TBL] [Abstract][Full Text] [Related]
5. Exploratory chemoinformatic analysis of cell type-selective anticancer drug targeting.
Shedden K; Rosania GR
Mol Pharm; 2004; 1(4):267-80. PubMed ID: 15981586
[TBL] [Abstract][Full Text] [Related]
6. Thymidine kinase, thymidylate synthase, and dihydropyrimidine dehydrogenase profiles of cell lines of the National Cancer Institute's Anticancer Drug Screen.
Grem JL; Danenberg KD; Behan K; Parr A; Young L; Danenberg PV; Nguyen D; Drake J; Monks A; Allegra CJ
Clin Cancer Res; 2001 Apr; 7(4):999-1009. PubMed ID: 11309351
[TBL] [Abstract][Full Text] [Related]
7. An informatics approach identifying markers of chemosensitivity in human cancer cell lines.
Amundson SA; Myers TG; Scudiero D; Kitada S; Reed JC; Fornace AJ
Cancer Res; 2000 Nov; 60(21):6101-10. PubMed ID: 11085534
[TBL] [Abstract][Full Text] [Related]
8. Identification of epidermal growth factor receptor and c-erbB2 pathway inhibitors by correlation with gene expression patterns.
Wosikowski K; Schuurhuis D; Johnson K; Paull KD; Myers TG; Weinstein JN; Bates SE
J Natl Cancer Inst; 1997 Oct; 89(20):1505-15. PubMed ID: 9337347
[TBL] [Abstract][Full Text] [Related]
9. Comprehensive analysis of pathway or functionally related gene expression in the National Cancer Institute's anticancer screen.
Huang R; Wallqvist A; Covell DG
Genomics; 2006 Mar; 87(3):315-28. PubMed ID: 16386875
[TBL] [Abstract][Full Text] [Related]
10. Novel prediction of anticancer drug chemosensitivity in cancer cell lines: evidence of moderation by microRNA expressions.
Yang DS
Annu Int Conf IEEE Eng Med Biol Soc; 2014; 2014():4780-6. PubMed ID: 25571061
[TBL] [Abstract][Full Text] [Related]
11. Web-based tools for mining the NCI databases for anticancer drug discovery.
Fang X; Shao L; Zhang H; Wang S
J Chem Inf Comput Sci; 2004; 44(1):249-57. PubMed ID: 14741034
[TBL] [Abstract][Full Text] [Related]
12. Identification of selective cytotoxic and synthetic lethal drug responses in triple negative breast cancer cells.
Gautam P; Karhinen L; Szwajda A; Jha SK; Yadav B; Aittokallio T; Wennerberg K
Mol Cancer; 2016 May; 15(1):34. PubMed ID: 27165605
[TBL] [Abstract][Full Text] [Related]
13. Methyl protogracillin (NSC-698792): the spectrum of cytotoxicity against 60 human cancer cell lines in the National Cancer Institute's anticancer drug screen panel.
Hu K; Yao X
Anticancer Drugs; 2001 Jul; 12(6):541-7. PubMed ID: 11460001
[TBL] [Abstract][Full Text] [Related]
14. Linking tumor cell cytotoxicity to mechanism of drug action: an integrated analysis of gene expression, small-molecule screening and structural databases.
Covell DG; Wallqvist A; Huang R; Thanki N; Rabow AA; Lu XJ
Proteins; 2005 May; 59(3):403-33. PubMed ID: 15778971
[TBL] [Abstract][Full Text] [Related]
15. NCI's anticancer drug screening program may not be selecting for clinically active compounds.
Brown JM
Oncol Res; 1997; 9(5):213-5. PubMed ID: 9306428
[TBL] [Abstract][Full Text] [Related]
16. Chemosensitivity profile of cancer cell lines and identification of genes determining chemosensitivity by an integrated bioinformatical approach using cDNA arrays.
Nakatsu N; Yoshida Y; Yamazaki K; Nakamura T; Dan S; Fukui Y; Yamori T
Mol Cancer Ther; 2005 Mar; 4(3):399-412. PubMed ID: 15767549
[TBL] [Abstract][Full Text] [Related]
17. Mining the National Cancer Institute Anticancer Drug Discovery Database: cluster analysis of ellipticine analogs with p53-inverse and central nervous system-selective patterns of activity.
Shi LM; Myers TG; Fan Y; O'Connor PM; Paull KD; Friend SH; Weinstein JN
Mol Pharmacol; 1998 Feb; 53(2):241-51. PubMed ID: 9463482
[TBL] [Abstract][Full Text] [Related]
18. Molecular modes of action of cephalotaxine and homoharringtonine from the coniferous tree Cephalotaxus hainanensis in human tumor cell lines.
Efferth T; Sauerbrey A; Halatsch ME; Ross DD; Gebhart E
Naunyn Schmiedebergs Arch Pharmacol; 2003 Jan; 367(1):56-67. PubMed ID: 12616342
[TBL] [Abstract][Full Text] [Related]
19. Prediction of drug efficacy for cancer treatment based on comparative analysis of chemosensitivity and gene expression data.
Wan P; Li Q; Larsen JE; Eklund AC; Parlesak A; Rigina O; Nielsen SJ; Björkling F; Jónsdóttir SÓ
Bioorg Med Chem; 2012 Jan; 20(1):167-76. PubMed ID: 22154557
[TBL] [Abstract][Full Text] [Related]
20. Characterization of anticancer agents by their growth inhibitory activity and relationships to mechanism of action and structure.
Keskin O; Bahar I; Jernigan RL; Beutler JA; Shoemaker RH; Sausville EA; Covell DG
Anticancer Drug Des; 2000 Apr; 15(2):79-98. PubMed ID: 10901296
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
